G1 Therapeutics rises on bone marrow treatment data

G1 Therapeutics

01/04/2022 15:37

** Shares of drugmaker  GTHX.O  rise 2.8% to $7.81 in morning
trade
    ** Late on Thursday, GTHX reported real-world study results
showing administration of its drug Cosela in patients with a
type of lung cancer before chemotherapy was associated with a
50% reduction in them experiencing severe blood-related adverse
events  urn:newsml:reuters.com:*:nGNX9tKB8K
    ** Cosela, intended to protect bone marrow cells from
chemotherapy-related damage, was approved by the U.S. FDA last
year for patients with small cell lung cancer
    ** Brokerage BTIG ("buy"; PT: $51) says the data "speaks to
the promise and potential of Cosela" adding that the focus is
now on the broader application of the drug
    ** Stock down 25.6% YTD, up to last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))